EHA 2014

 
 
 

Milano Congressi, site of the 19th Congress of the European Hematology Association (EHA).

The 19th Congress of EHA took place June 12-15, 2014, in Milan, Italy.

 

Study validates drug’s efficacy in CLL/SLL

Jen Smith Read Article
Published: 07/03/14

EHA_2014_crowd_Credit_EHA_230.jpg
Crowd at EHA 2014
Photo courtesy of EHA

Results of the phase 3 RESONATE trial suggest ibrutinib can improve response and survival rates in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), when compared to ofatumumab. Ibrutinib conferred these benefits irrespective of baseline clinical characteristics or molecular features, including 17p deletion. Atrial fibrillation and bleeding-related events were more common with ibrutinib. [Read Article]

Phase 2 results lead to breakthrough designation

Jen Smith Read Article
Published: 07/02/14

EHA_2014_Credit_EHA_230.jpg
Attendees at EHA 2014
Photo courtesy of EHA

The US Food and Drug Administration (FDA) has granted the bispecific antibody blinatumomab breakthrough designation for the treatment of adults with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL). The decision was based on promising results of a phase 2 trial, which were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) and the 19th Congress of the European Hematology Association (EHA). [Read Article]

QOL data support ATRA-ATO in APL

Jen Smith Read Article
Published: 07/01/14

efficace_fabio_EHA_2014_240.jpg
Fabio Efficace, PhD

Quality of life (QOL) data support the use of all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) in patients with acute promyelocytic leukemia (APL), a GIMEMA researcher has reported. Previously released data from a phase 3 study showed that ATRA-ATO can improve survival rates in APL patients when compared to ATRA plus chemotherapy. Now, a QOL assessment of these same patients suggests ATO can confer additional benefits. [Read Article]

Thalidomide offers short-term efficacy in HHT

Jen Smith Read Article
Published: 06/25/14

thalidomide_bottles_240.jpg
Bottles of thalidomide

Results of a phase 2 trial suggest thalidomide can elicit solid—though not necessarily durable—responses among patients with hereditary hemorrhagic telangiectasia (HHT) suffering from severe, recurrent epistaxis. All 29 evaluable patients responded to thalidomide, with 4 achieving a complete response. Unfortunately, 11 patients relapsed at a median of 43 weeks. But re-treatment was possible for a few patients and did prompt additional responses. [Read Article]

Inhibitor shows promise for hematologic disorders

Jen Smith Read Article
Published: 06/24/14

EHA_2014_attendees_Credit_EHA_230.jpg
Attendees at EHA 2014
Photo courtesy of EHA

The IDH2 inhibitor AG-221 is well-tolerated and exhibits durable clinical activity in patients with hematologic disorders, results of a phase 1 study suggest. The drug prompted responses in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). Fourteen of 25 patients achieved a response, and 12 of those responses are ongoing. Most adverse events (AEs) were grade 1 or 2 in nature. [Read Article]

Studies confirm importance of CALR mutation in PMF

Jen Smith Read Article
Published: 06/20/14

EHA_2104_audience_Credit_EHA_230.jpg
Audience at EHA 2014
Photo courtesy of EHA

Two new studies appear to confirm the prognostic significance of CALR mutations in patients with primary myelofibrosis (PMF). One study showed that PMF patients with mutated CALR had prolonged overall survival (OS) compared to patients with wild-type CALR. And additional subclonal mutations did not impair the positive impact of CALR mutations. Another study suggested that indels in exon 9 of CALR are founding driver mutations in PMF. [Read Article]

Eltrombopag meets primary endpoint in children with ITP

HT Staff Read Article
Published: 06/19/14

pediatrician_and_patient_Credit_Logan_Tuttle_230.jpg
Doctor examining child
Credit: Logan Tuttle

Eltrombopag can elicit consistent platelet responses in children with immune thrombocytopenia (ITP), according to research presented at the 19th Congress of the European Hematology Association (EHA). Results of the phase 3 PETIT2 study showed that eltrombopag can significantly improve platelet counts in pediatric ITP patients, when compared to placebo. In fact, the drug enabled 61% of children to stop taking or reduce the dose of their other ITP medication.  [Read Article]

Approach can reduce drug-induced TLS

Jen Smith Read Article
Published: 06/18/14

EHA_2014_session_Credit_EHA_230.jpg
Session at EHA 2014
Photo courtesy of EHA

The BCL-2 inhibitor ABT-199 may be a feasible treatment option for patients with chronic lymphocyctic leukemia/small lymphocytic lymphoma (CLL/SLL), according to research presented at the 19th Congress of the European Hematology Association (EHA). Previous results showed that ABT-199 can elicit responses in CLL/SLL patients, but it can also induce tumor lysis syndrome (TLS). In fact, 2 TLS-related deaths prompted the temporary suspension of enrollment in trials of ABT-199. [Read Article]

Cream provides relief for leg ulcers in SCD

Jen Smith Read Article
Published: 06/17/14

EHA_sign_2014_255.jpg

Results of a phase 1 study indicate that topical sodium nitrate is safe and effective for treating leg ulcers in patients with sickle cell disease (SCD). The cream significantly decreased the size of leg ulcers overall, healed ulcers in 6 of the 18 patients studied, and reduced pain levels, seemingly independent of wound healing. A few patients did experience short-lived burning at the treatment site, and some experienced a temporary, asymptomatic drop . . . [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}